Refresh, Revitalize, and Rejuvenate
301.570.0030 (MD)
202.965.7546 (DC)

Restylane® Refyne & Restylane® Defyne Are Now Approved! 


Restylane® Refyne & Restylane® Defyne Are Now Approved! 

Restylane Refyne Restylane Defyne
 
Next-Generation Flexible Hyaluronic Acid Dermal Fillers Provide Natural-Looking Results Through XpresHAn Technology
 
Galderma, a global leader focused on medical solutions in skin health, recently announced that it has received U.S. Food and Drug Administration (FDA) approval for two new products for the treatment of nasolabial folds (NLF) or “laugh lines.”
 
Restylane® Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane® Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.
 
Unlike other fillers that are already on the market, Restylane Defyne and Restylane Refyne incorporate a special XpresHAn technology, deeming these products as next-generation hyaluronic acid fillers.
 
The XpresHAn technology allows for the product to move within the face as facial expressions are made to prevent a fake, injected or unnatural look.
 
“Even with current approved options, many of my patients are still looking for different solutions to treat their laugh lines,” said Boca Raton-based oculoplastic surgeon and Restylane® Refyne clinical investigator, Steven Fagien, MD.
 
“These new products are flexible and are designed to meet different patient needs. I am excited to offer these next-generation hyaluronic acid (HA) dermal fillers in my practice.”
 
“Restylane® Refyne and Restylane® Defyne are the latest FDA-approved advancements in HA dermal fillers and align with Galderma’s mission to help individuals achieve natural-looking results through treatments with a long-standing history of proven safety and efficacy,” said Kelly Huang, PhD – VP & General Manager of the U.S. Aesthetic and Corrective business of Galderma.
 
“We saw an opportunity to address a common concern for patients who have not yet tried a dermal filler by designing gels that provide natural-looking results. With these new brands, the Restylane® family of products now represents the broadest offering of HA dermal fillers in the U.S.”
 
The FDA approval was based on two pivotal, double-blinded, randomized, active-controlled Phase 3 studies investigating Restylane® Refyne and Restylane® Defyne (involving 171 and 162 subjects, respectively) to evaluate their safety and effectiveness.
 
In both studies, Restylane® Refyne and Restylane® Defyne met the studies’ endpoints, with both products showing a clinically meaningful improvement in wrinkle severity for up to 12 months in the majority of patients.
 
Study investigators used the Wrinkle Severity Rating Scale (WSRS), a validated 5-point measure of the size and depth of the wrinkles, with grade 1 defined as absence of wrinkles and grade 5 as extremely deep and long wrinkles.
 
Investigators reported that 79 percent of Restylane® Refyne subjects and 77 percent of Restylane® Defyne subjects had at least a 1-grade improvement on the WSRS after six weeks.
 

 
Subjects also performed self-assessments (SSA) of wrinkle severity, with most subjects reporting at least a one-grade improvement in SSA scores with Restylane® Refyne and with Restylane® Defyne after six weeks.
 
“Many of my patients are interested to learn about the latest products that can help them achieve natural-looking results, but are oftentimes unsure about starting dermal fillers,” said San Diego-based board-certified dermatologist Mitch Goldman, MD.
 
“The introduction of these next-generation HA dermal fillers with XpresHAn Technology has the potential to change my patients’ views on fillers. Restylane® Refyne and Restylane® Defyne provide options for patients who want to make sure they can achieve results that provide options for patients who want to make sure they can achieve natural-looking results which is a key need my patients express every day.”
 
After initial treatment, injection site responses (redness, swelling, bruising, lump/bump formation, pain/tenderness) were predominantly mild or moderate in intensity, temporary (typically with a duration of one to two weeks), and similar for the Restylane® products.
 
Check back soon for more information on when Restylane Refyne Washington DC and Restylane Defyne Washington DC will be available.


contact us


Want More Information?

Call Us!

301 - 570 - 0030 (MD)

202 - 965 - 7546 (DC)

or

Fill Out The Form Below

  
  • Contact Us

    Your Name (required)

    Your Email (required)

    Subject

    (Please Specify Office Location)

    Your Message

    captcha

  • Like Us on Facebook

  • Recent Posts

  • testimonials


    I love coming to CSI. The staff is amazing and they make me feel so relaxed... Read more


    My entire family have been patients of Gloria Perez, their Medical Esthetician, for years... Read more


    The office is clean, bright and you feel very comfortable whether you are there for a facial, botox, fillers, laser treatments, or a make-up lesson. Susanne and Jessica are my “go to ” people... Read more


    I have been going to the Cosmetic Skin Institute for a couple of years. I could not be happier... Read more

    news


    Introducing HydraFacial

    HydraFacial uses patented technology to cleanse, extract, and hydrate. HydraFacial super serums are made with nourishing ingredients.....

    Read more
    Collagen P.I.N. Microneedling

    The Collagen P.I.N. microneedling treatment triggers new collagen synthesis, yet does not pose the risk of permanent scarring. The result is smoother, firmer and younger-looking skin......

    Read more

    our locations


    Cosmetic Skin Institute

    CSI Olney
    18111 Prince Philip Drive Suite 120
    Olney, MD 20832
    Phone: (301)570-0030

    CSI DC
    4400 MacArthur Blvd NW Suite 102A
    Washington, DC 20007
    Phone: (202)965-7546

    Jessica Lee
    (510)754-4951

    Judy Silvero
    (301)213-6131
    Copyright 2017 Cosmetic Skin Institute